Swiss drugs industry supplier Lonza plans to cut 500 jobs, including 400 at its main plant in southern Switzerland, as it grapples with low-cost competition, a strong Swiss franc, and higher raw material prices.
Perhaps a small number of the eliminated jobs can be attributed to setbacks in the FoB partnership with Teva (#msg-80236315, #msg-34930012).